Latest Lipocine Inc (LPCN) Headlines
Lipocine to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 26 Annual ROTH Conference on Wednesday, March 12, 2014 at 1:00 p.m. ET.
Lipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy
GlobeNewswire - Mon Feb 10, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study. The trial is designed to evaluate the safety and efficacy of LPCN 1021, an oral testosterone replacement therapy, in hypogonadal men with low testosterone (Low T; www.lowtstudy.com). Approximately 300 patients are expected to be enrolled in multiple sites in the United States. The company expects to report top-line efficacy data for the trial in the second half of 2014 with a New Drug Application ("NDA") filing with the U.S. Food and Drug Administration (FDA) anticipated in the second half of 2015.
Lipocine to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 2014 Leerink Global Healthcare Conference on Wednesday February 12, 2014 at 10:15 a.m. EST. The conference is being held at the Waldorf Astoria in New York, NY.
Lipocine Announces New Appointments to Its Board of Directors
GlobeNewswire - Tue Jan 07, 3:00PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including the appointments of Dr. Stephen Hill, Mr. Jeffrey Fink, and Dr. R. Dana Ono, and the retirements of Chairman Dr. William Higuchi and Mr. Gordhan Patel. Dr. Mahesh Patel, Lipocine President and Chief Executive Officer, has assumed the position of Chairman of the Board and Dr. Higuchi will serve as the Company's Chief Scientific Advisor.
Lipocine Chairman Receives Honorary Doctor of Science Degree From the University of Michigan
GlobeNewswire - Fri Dec 13, 3:30PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced that Dr. William I. Higuchi will receive an honorary Doctor of Science degree from the University of Michigan at the winter commencement ceremony, Sunday December 15, 2013.
Lipocine Inc. Announces Exercise and Closing of Over-Allotment Option
GlobeNewswire - Fri Dec 06, 3:00PM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the underwriters of its previously announced public offering have fully exercised their option to purchase an additional 223,800 shares of Lipocine common stock at a price of $8.25 per share, for additional gross proceeds of approximately $1.8 million. The gross proceeds to Lipocine from the offering, including the exercise of the over-allotment option, will be approximately $14.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Lipocine.
Lipocine Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Nov 27, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced the pricing of an underwritten public offering of 1,492,000 shares of its common stock at a price to the public of $8.25 per share. The gross proceeds from this offering to Lipocine are expected to be approximately $12.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Lipocine. Lipocine has granted the underwriters a 30-day option to purchase up to an aggregate of 223,800 additional shares of common stock. The offering is expected to close on or about November 29, 2013, subject to customary closing conditions. Lipocine expects to use the net proceeds of this offering to conduct clinical trials for its lead product candidate LPCN 1021 and other product candidates and the balance for working capital and general corporate purposes.
Market Research: Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/34w87h/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013" report to their offering. 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder. Scope - A snapshot of the global therapeutic scenario for Female Hypoactive Sexual Desire Disorder. - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned NexMed, Inc. Palatin Technologies, Inc. ANI Pharmaceuticals, Inc. Fabre-Kramer Pharmaceuticals, Inc. Lipocine Inc. For more information visit http://www.researchandmarkets.com/research/34...hypoactive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lipocine Inc. Appoints Morgan Brown as Executive Vice President and Chief Financial Officer
Business Wire - Mon Sep 16, 7:00AM CDT
Lipocine Inc. ("Lipocine") (OTCQB/OTCBB: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown has joined the Company as Executive Vice President and Chief Financial Officer ("CFO"). Mr. Brown has more than 20 years of financial and accounting experience, including over 13 years in financial management of life science companies.
Male Hypogonadism - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4f82bh/male_hypogonadism) has announced the addition of the "Male Hypogonadism - Pipeline Review, H2 2013" report to their offering. 'Male Hypogonadism - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Hypogonadism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Hypogonadism. Scope - A snapshot of the global therapeutic scenario for Male Hypogonadism. - A review of the Male Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Male Hypogonadism pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Endo Pharmaceuticals Holdings Inc. Merck & Co., Inc. Novartis AG Clarus Therapeutics, Inc. Ascend Therapeutics, Inc. Repros Therapeutics Inc. M et P Pharma AG APTYS Pharmaceuticals Pantarhei Bioscience BV Monosol Rx, LLC Lipocine Inc. Diurnal Ltd For more information visit http://www.researchandmarkets.com/research/4f...pogonadism About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lipocine to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 26 Annual ROTH Conference on Wednesday, March 12, 2014 at 1:00 p.m. ET.
Lipocine Announces First Patient Dosed in Phase 3 Study for Oral Testosterone Replacement Therapy
GlobeNewswire - Mon Feb 10, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study. The trial is designed to evaluate the safety and efficacy of LPCN 1021, an oral testosterone replacement therapy, in hypogonadal men with low testosterone (Low T; www.lowtstudy.com). Approximately 300 patients are expected to be enrolled in multiple sites in the United States. The company expects to report top-line efficacy data for the trial in the second half of 2014 with a New Drug Application ("NDA") filing with the U.S. Food and Drug Administration (FDA) anticipated in the second half of 2015.
Lipocine to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Tue Feb 04, 9:48PM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 2014 Leerink Global Healthcare Conference on Wednesday February 12, 2014 at 10:15 a.m. EST. The conference is being held at the Waldorf Astoria in New York, NY.
Lipocine Announces New Appointments to Its Board of Directors
GlobeNewswire - Tue Jan 07, 3:00PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including the appointments of Dr. Stephen Hill, Mr. Jeffrey Fink, and Dr. R. Dana Ono, and the retirements of Chairman Dr. William Higuchi and Mr. Gordhan Patel. Dr. Mahesh Patel, Lipocine President and Chief Executive Officer, has assumed the position of Chairman of the Board and Dr. Higuchi will serve as the Company's Chief Scientific Advisor.
Lipocine Chairman Receives Honorary Doctor of Science Degree From the University of Michigan
GlobeNewswire - Fri Dec 13, 3:30PM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced that Dr. William I. Higuchi will receive an honorary Doctor of Science degree from the University of Michigan at the winter commencement ceremony, Sunday December 15, 2013.
Lipocine Inc. Announces Exercise and Closing of Over-Allotment Option
GlobeNewswire - Fri Dec 06, 3:00PM CST
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the underwriters of its previously announced public offering have fully exercised their option to purchase an additional 223,800 shares of Lipocine common stock at a price of $8.25 per share, for additional gross proceeds of approximately $1.8 million. The gross proceeds to Lipocine from the offering, including the exercise of the over-allotment option, will be approximately $14.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Lipocine.
Lipocine Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Nov 27, 7:30AM CST
Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced the pricing of an underwritten public offering of 1,492,000 shares of its common stock at a price to the public of $8.25 per share. The gross proceeds from this offering to Lipocine are expected to be approximately $12.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Lipocine. Lipocine has granted the underwriters a 30-day option to purchase up to an aggregate of 223,800 additional shares of common stock. The offering is expected to close on or about November 29, 2013, subject to customary closing conditions. Lipocine expects to use the net proceeds of this offering to conduct clinical trials for its lead product candidate LPCN 1021 and other product candidates and the balance for working capital and general corporate purposes.
Market Research: Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013
M2 - Thu Nov 07, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/34w87h/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013" report to their offering. 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder. Scope - A snapshot of the global therapeutic scenario for Female Hypoactive Sexual Desire Disorder. - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned NexMed, Inc. Palatin Technologies, Inc. ANI Pharmaceuticals, Inc. Fabre-Kramer Pharmaceuticals, Inc. Lipocine Inc. For more information visit http://www.researchandmarkets.com/research/34...hypoactive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lipocine Inc. Appoints Morgan Brown as Executive Vice President and Chief Financial Officer
Business Wire - Mon Sep 16, 7:00AM CDT
Lipocine Inc. ("Lipocine") (OTCQB/OTCBB: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown has joined the Company as Executive Vice President and Chief Financial Officer ("CFO"). Mr. Brown has more than 20 years of financial and accounting experience, including over 13 years in financial management of life science companies.
Male Hypogonadism - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4f82bh/male_hypogonadism) has announced the addition of the "Male Hypogonadism - Pipeline Review, H2 2013" report to their offering. 'Male Hypogonadism - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Hypogonadism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Hypogonadism. Scope - A snapshot of the global therapeutic scenario for Male Hypogonadism. - A review of the Male Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Male Hypogonadism pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Endo Pharmaceuticals Holdings Inc. Merck & Co., Inc. Novartis AG Clarus Therapeutics, Inc. Ascend Therapeutics, Inc. Repros Therapeutics Inc. M et P Pharma AG APTYS Pharmaceuticals Pantarhei Bioscience BV Monosol Rx, LLC Lipocine Inc. Diurnal Ltd For more information visit http://www.researchandmarkets.com/research/4f...pogonadism About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
